Phase III study to determine the impact of gemtuzumab ozogamicin, in association with standard chemotherapy, on the levels of minimal residual disease, and the role of glasdegib as post-transplant maintenance, in adult patients, aged between 18 and 60 years, affected by Acute Myeloid Leukemia not previously treated, newly diagnosed, at favorable or intermediate risk.
Project objectivesThe main objective of this study is to evaluate the impact of gemtuzumab ozogamicin, in association with standard chemotherapy, on the levels of minimal residual disease, and the role of glasdegib as post-transplant maintenance, in adult patients, aged between 18 and 60 years, affected by acute myeloid leukemia. previously treated, newly diagnosed. |
Start and end date |
| 26 February 2020 |
Project Manager |
| Luigi Rigacci - Principal Investigator |
Funding source(s). |
| • GIMEMA |
